Assessing Risk of Bias in Included Studies

8.

[1]  J D Emerson,et al.  An empirical study of the possible relation of treatment differences to quality scores in controlled randomized clinical trials. , 1990, Controlled clinical trials.

[2]  T. Cleophas.  The performance of the two-stage analysis of two-treatment, two-period crossover trials. , 1991, Statistics in medicine.

[3]  D. Altman,et al.  Baseline comparisons in randomized clinical trials. , 1991, Statistics in medicine.

[4]  C D Naylor,et al.  Incorporating variations in the quality of individual randomized trials into meta-analysis. , 1992, Journal of clinical epidemiology.

[5]  D J Newell,et al.  Intention-to-treat analysis: implications for quantitative and qualitative research. , 1992, International journal of epidemiology.

[6]  G. Guyatt,et al.  The Science of Reviewing Research a , 1993, Annals of the New York Academy of Sciences.

[7]  J. Noseworthy,et al.  The impact of blinding on the results of a randomized, placebo‐controlled multiple sclerosis clinical trial , 1994, Neurology.

[8]  K. Schulz,et al.  Subverting randomization in controlled trials. , 1995, JAMA.

[9]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.

[10]  K. Woods.  Mega-trials and management of acute myocardial infarction , 1995, The Lancet.

[11]  A R Jadad,et al.  Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. , 1995, Controlled clinical trials.

[12]  S. Walter,et al.  Empirical evidence of bias in infertility research: overestimation of treatment effect in crossover trials using pregnancy as the outcome measure. , 1996, Fertility and sterility.

[13]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[14]  A R Jadad,et al.  Assessing the Quality of Randomized Controlled Trials: Current Issues and Future Directions , 1996, International Journal of Technology Assessment in Health Care.

[15]  C D Naylor,et al.  Meta-analysis and the meta-epidemiology of clinical research , 1997, BMJ.

[16]  D. Cook,et al.  Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? , 1998, The Lancet.

[17]  Crossover designs versus parallel studies in infertility research. , 1998, Fertility and sterility.

[18]  Douglas G Altman,et al.  How to randomise , 1999, BMJ.

[19]  M. Egger,et al.  The hazards of scoring the quality of clinical trials for meta-analysis. , 1999, JAMA.

[20]  S. Casswell,et al.  What is meant by intention to treat analysis? Survey of published randomised controlled trials , 1999 .

[21]  R. Peto.  Failure of randomisation by “sealed” envelope , 1999, The Lancet.

[22]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[23]  J M Lachin,et al.  Statistical considerations in the intent-to-treat principle. , 2000, Controlled clinical trials.

[24]  I. Pavord,et al.  Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial , 2000, The Lancet.

[25]  P. Williamson,et al.  Bias in meta‐analysis due to outcome variable selection within studies , 2000 .

[26]  C. Adams,et al.  Unpublished rating scales: A major source of bias in randomised controlled trials of treatments for schizophrenia , 2000, British Journal of Psychiatry.

[27]  R. Bellomo,et al.  Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial , 2000, The Lancet.

[28]  A. Berber,et al.  Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. , 2000, Obesity research.

[29]  Douglas G Altman,et al.  Systematic reviews in health care: Assessing the quality of controlled clinical trials. , 2001, BMJ.

[30]  M. Trip,et al.  Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial , 2001, The Lancet.

[31]  G. Guyatt,et al.  Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. , 2001, JAMA.

[32]  Andrew J Vickers,et al.  The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study , 2001, BMC medical research methodology.

[33]  Christian Gluud,et al.  Reported Methodologic Quality and Discrepancies between Large and Small Randomized Trials in Meta-Analyses , 2001, Annals of Internal Medicine.

[34]  G. de Gaetano.  Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. , 2001, Lancet.

[35]  S Greenland,et al.  On the bias produced by quality scores in meta-analysis, and a hierarchical view of proposed solutions. , 2001, Biostatistics.

[36]  Douglas G Altman,et al.  Statistical methods for assessing the influence of study characteristics on treatment effects in ‘meta‐epidemiological’ research , 2002, Statistics in medicine.

[37]  G. Guyatt,et al.  Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis , 2002, BMJ : British Medical Journal.

[38]  I. Chalmers,et al.  The Landscape and Lexicon of Blinding in Randomized Trials , 2002, Annals of Internal Medicine.

[39]  Kenneth F Schulz,et al.  Allocation concealment in randomised trials: defending against deciphering , 2002, The Lancet.

[40]  Kenneth F Schulz,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Trialists Rely on the Security of Unpredictability. in the Forcing Cosmetic Credibility Unequal Group Sizes in Randomised Trials: Guarding against Guessing , 2022 .

[41]  Kenneth F Schulz,et al.  Generation of allocation sequences in randomised trials: chance, not choice , 2002, The Lancet.

[42]  S. Hahn,et al.  Investigation of within-study selective reporting in clinical research: follow-up of applications submitted to a local research ethics committee. , 2002, Journal of evaluation in clinical practice.

[43]  Ethan M Balk,et al.  Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. , 2002, JAMA.

[44]  G. Guyatt,et al.  In the dark: the reporting of blinding status in randomized controlled trials. , 2002, Journal of clinical epidemiology.

[45]  Douglas G Altman,et al.  Meta-analyses involving cross-over trials: methodological issues. , 2002, International journal of epidemiology.

[46]  D. Torgerson,et al.  Evidence for risk of bias in cluster randomised trials: review of recent trials published in three general medical journals , 2003, BMJ : British Medical Journal.

[47]  B. Beermann,et al.  Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications , 2003, BMJ : British Medical Journal.

[48]  Douglas G. Altman,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[49]  David J Spiegelhalter,et al.  Bayesian approaches to multiple sources of evidence and uncertainty in complex cost‐effectiveness modelling , 2003, Statistics in medicine.

[50]  Anastasia Ivanova,et al.  Minimizing predictability while retaining balance through the use of less restrictive randomization procedures , 2003, Statistics in medicine.

[51]  J. Sterne,et al.  How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. , 2003, Health technology assessment.

[52]  Douglas G Altman,et al.  Analysis and reporting of factorial trials: a systematic review. , 2003, JAMA.

[53]  D. Altman,et al.  Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research , 2004, Canadian Medical Association Journal.

[54]  Duff Waring,et al.  Turning a blind eye: the success of blinding reported in a random sample of randomised, placebo controlled trials , 2004, BMJ : British Medical Journal.

[55]  Ian R White,et al.  Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals , 2004, Clinical trials.

[56]  A. Hrõbjartsson,et al.  Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. , 2004, JAMA.

[57]  Deborah Ashby,et al.  Lessons for cluster randomized trials in the twenty-first century: a systematic review of trials in primary care , 2004, Clinical trials.

[58]  Lesley A Stewart,et al.  Investigating patient exclusion bias in meta-analysis. , 2004, International journal of epidemiology.

[59]  D. Torgerson,et al.  Differential recruitment in a cluster randomized trial in primary care: the experience of the UK Back pain, Exercise, Active management and Manipulation (UK BEAM) feasibility study , 2005, Clinical trials.

[60]  D. Altman,et al.  Outcome selection bias in meta-analysis , 2005, Statistical methods in medical research.

[61]  Julia Brown,et al.  Minimization—reducing predictability for multi‐centre trials whilst retaining balance within centre , 2005, Statistics in medicine.

[62]  S. Thompson,et al.  Clustering by health professional in individually randomised trials , 2005, BMJ : British Medical Journal.

[63]  Gordon H Guyatt,et al.  Randomized trials stopped early for benefit: a systematic review. , 2005, JAMA.

[64]  Vance W Berger,et al.  Quantifying the Magnitude of Baseline Covariate Imbalances Resulting from Selection Bias in Randomized Clinical Trials , 2005, Biometrical journal. Biometrische Zeitschrift.

[65]  S. Hahn,et al.  Methodological bias in cluster randomised trials , 2005, BMC medical research methodology.

[66]  I. Boutron,et al.  A review of blinding in randomized controlled trials found results inconsistent and questionable. , 2005, Journal of clinical epidemiology.

[67]  D. Altman,et al.  Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors , 2005, BMJ : British Medical Journal.

[68]  C. Gamble,et al.  Identification and impact of outcome selection bias in meta‐analysis , 2005, Statistics in medicine.

[69]  A. Hrõbjartsson,et al.  Constraints on publication rights in industry-initiated clinical trials. , 2006, JAMA.

[70]  P. Gøtzsche,et al.  Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations , 2006, Trials.

[71]  P. Gøtzsche,et al.  Voriconazole versus amphotericin B in cancer patients with neutropenia. , 2006, The Cochrane database of systematic reviews.

[72]  Sally Hung-Hsin Lee,et al.  Use of the two-stage procedure for analysis of cross-over trials in four aspects of medical statistics , 2006 .

[73]  Asbjørn Hróbjartsson,et al.  Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors , 2006, Clinical trials.

[74]  D. Sackett,et al.  Methods of Blinding in Reports of Randomized Controlled Trials Assessing Pharmacologic Treatments: A Systematic Review , 2006, PLoS medicine.

[75]  Peter C Gøtzsche,et al.  Data extraction errors in meta-analyses that use standardized mean differences. , 2007, JAMA.

[76]  J. Hilden,et al.  Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. , 2007, International journal of epidemiology.

[77]  Ezekiel Uba Nwose,et al.  The Lancet Handbook of Essential Concepts in Clinical Research , 2007 .

[78]  G. Guyatt,et al.  Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. , 2007, JAMA.

[79]  G. Guyatt,et al.  Systematic reviewers neglect bias that results from trials stopped early for benefit. , 2007, Journal of clinical epidemiology.

[80]  E. Cobo,et al.  Discordance between reported intention-to-treat and per protocol analyses. , 2007, Journal of clinical epidemiology.

[81]  D. Altman,et al.  Chapter 8: Assessing risk of bias in included studies , 2008 .

[82]  Douglas G Altman,et al.  Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study , 2008, BMJ : British Medical Journal.